Research Article
Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group.
British Medical Journal 1990; 300 doi: https://doi.org/10.1136/bmj.300.6724.573 (Published 03 March 1990) Cite this as: British Medical Journal 1990;300:573
Related articles
- No related articles found.
See more
- Whole brain radiotherapy for brain metastasesBMJ December 05, 2016, 355 i6483; DOI: https://doi.org/10.1136/bmj.i6483
- Biological treatment is approved for severe eosinophilic asthmaBMJ December 01, 2016, 355 i6472; DOI: https://doi.org/10.1136/bmj.i6472
- Preserving fertility in girls and young women with cancerBMJ November 30, 2016, 355 i6145; DOI: https://doi.org/10.1136/bmj.i6145
- Glucagon-like peptide-1 receptor agonists and risk of breast cancerBMJ October 20, 2016, 355 i5519; DOI: https://doi.org/10.1136/bmj.i5519
- Anabolic steroid useBMJ October 13, 2016, 355 i5023; DOI: https://doi.org/10.1136/bmj.i5023
Cited by...
- HIF-PHIs for Anemia Management in CKD: Potential and Uncertainty ASCEND
- Effect of a 3-Year Lifestyle Intervention in Patients with Chronic Kidney Disease: A Randomized Clinical Trial
- Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies
- Neither Hematocrit Normalization nor Exercise Training Restores Oxygen Consumption to Normal Levels in Hemodialysis Patients
- Critical and Honest Conversations: The Evidence Behind the "Choosing Wisely" Campaign Recommendations by the American Society of Nephrology
- Pedometer-Assessed Physical Activity in Children and Young Adults with CKD
- Erythropoietic Stimulating Agents and Quality of a Patient's Life: Individualizing Anemia Treatment
- The New FDA Labeling for ESA--Implications for Patients and Providers
- Intradialytic Hypotension and Vascular Access Thrombosis
- Nadir Hemoglobin Levels after Discontinuation of Epoetin in Hemodialysis Patients
- Use of erythropoietins in patients with renal transplants
- Is Nephrology More at Ease Than Oncology with Erythropoiesis-Stimulating Agents? Treatment Guidelines and an Update on Benefits and Risks
- Erythropoietin Therapy, Hemoglobin Targets, and Quality of Life in Healthy Hemodialysis Patients: A Randomized Trial
- Erythropoietin Therapy and Left Ventricular Mass Index in CKD and ESRD Patients: A Meta-Analysis
- Arterial Hypertension Induced by Erythropoietin and Erythropoiesis-Stimulating Agents (ESA)
- Health-Related Quality of Life and Hemoglobin Levels in Chronic Kidney Disease Patients
- Hemoglobin Targets and Blood Transfusions in Hemodialysis Patients without Symptomatic Cardiac Disease Receiving Erythropoietin Therapy
- Ferumoxytol for Treating Iron Deficiency Anemia in CKD
- Hemoglobin Variability in Dialysis Patients
- Do We Know the Correct Hemoglobin Target for Anemic Patients with Chronic Kidney Disease?
- Exercise Performance Falls over Time in Patients with Chronic Kidney Disease Despite Maintenance of Hemoglobin Concentration
- Associations between Changes in Hemoglobin and Administered Erythropoiesis-Stimulating Agent and Survival in Hemodialysis Patients
- Elevated Erythropoietin Receptor and Transforming Growth Factor-{beta}1 Expression in Stenotic Arteriovenous Fistulae Used for Hemodialysis
- Increasing the Hematocrit Has a Beneficial Effect on Quality of Life and Is Safe in Selected Hemodialysis Patients
- Cost-effectiveness of captopril therapy after myocardial infarction